कृपया अन्य खोज का प्रयास करें
StemRIM, a biotechnology company, develops regeneration medicines for the treatment of intractable diseases. The company develops PJ1, a regeneration induction medicine HMGB1 peptides, which is in Phase II clinical trials for the treatment of epidermolysis bullosa, cerebral infarction, osteoarthritis, and chronic liver disease, as well as cardiomyopathy. Its pre-clinical stage products include PJ2 and PJ3 to treat multiple tissue damage disease; PJ4, an autologous cell sampling device for medical treatment; and PJ5, a stem cell gene therapy. StemRIM was incorporated in 2006 and is based in Ibaraki, Japan.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Katsuto Tamai | - | - | Director |
Yoichiro Shimada | - | - | External Audit & Supervisory Board Member |
Akihiro Mizukami | 67 | - | External Audit & Supervisory Board Member |
Yoji Kudo | - | - | Full-Time External Audit & Supervisory Board Member |
Noriko Sawai | - | 2019 | Independent Outside Director |
Masatsune Okajima | 55 | 2019 | President, CEO & Representative Director |
Tadahiro Nagai | - | 2020 | Independent Outside Director |
Kensuke Tomita | 74 | 2013 | Executive Chairman |
Katsuto Tamai | - | 2022 | Chief Scientific Officer, Director of Basic Research Department & Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है